Dr. Dreicer on Ongoing Trials in Prostate Cancer

Robert Dreicer, MD
Published Online: Tuesday, Jul 18, 2017



Robert Dreicer, MD, professor, University of Virginia Health System, discusses ongoing trials investigating emerging treatments for patients with prostate cancer.

There are ongoing trials suggesting that VT-464 may have some theoretical advantages for patients who have splice variants. It appears to be a safe agent with activity but the extent of the activity is still unknown.

EPI-506 is a different type of AR antagonist, which may also have activity in splice variants, however the phase II data is not yet mature.
 


Robert Dreicer, MD, professor, University of Virginia Health System, discusses ongoing trials investigating emerging treatments for patients with prostate cancer.

There are ongoing trials suggesting that VT-464 may have some theoretical advantages for patients who have splice variants. It appears to be a safe agent with activity but the extent of the activity is still unknown.

EPI-506 is a different type of AR antagonist, which may also have activity in splice variants, however the phase II data is not yet mature.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x